-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14

Benzinga·11/13/2026 15:22:04
语音播报
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.